CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Mersana Therapeutics, Inc. - MRSN CFD

    -
    0%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread -
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Mersana Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* N/A
    Open* N/A
    1-Year Change* N/A
    Day's Range* N/A
    52 wk Range 0.80-9.62
    Average Volume (10 days) 2.21M
    Average Volume (3 months) 158.38M
    Market Cap 154.25M
    P/E Ratio -100.00K
    Shares Outstanding 120.51M
    Revenue 38.72M
    EPS -2.05
    Dividend (Yield %) N/A
    Beta 1.42
    Next Earnings Date Nov 6, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low

    Mersana Therapeutics, Inc. Events

    Time (UTC) Country Event
    Monday, November 6, 2023

    Time (UTC)

    13:30

    Country

    US

    Event

    Q3 2023 Mersana Therapeutics Inc Earnings Release
    Q3 2023 Mersana Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    Monday, February 26, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 Mersana Therapeutics Inc Earnings Release
    Q4 2023 Mersana Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 26.581 0.043 0.828 42.123 10.594
    Revenue 26.581 0.043 0.828 42.123 10.594
    Total Operating Expense 230.348 168.901 88.938 72.323 76.249
    Selling/General/Admin. Expenses, Total 56.963 36.888 21.902 17.283 16.334
    Research & Development 173.385 132.013 67.036 55.04 59.915
    Depreciation / Amortization
    Operating Income -203.767 -168.858 -88.11 -30.2 -65.655
    Interest Income (Expense), Net Non-Operating -0.445 -1.202 0.065 1.992 1.398
    Other, Net
    Net Income Before Taxes -204.212 -170.06 -88.045 -28.208 -64.257
    Net Income After Taxes -204.212 -170.06 -88.045 -28.208 -64.257
    Net Income Before Extra. Items -204.212 -170.06 -88.045 -28.208 -64.257
    Net Income -204.212 -170.06 -88.045 -28.208 -64.257
    Income Available to Common Excl. Extra. Items -204.212 -170.06 -88.045 -28.208 -64.257
    Income Available to Common Incl. Extra. Items -204.212 -170.06 -88.045 -28.208 -64.257
    Diluted Net Income -204.212 -170.06 -88.045 -28.208 -64.257
    Diluted Weighted Average Shares 93.6542 70.5809 61.4852 43.4921 23.0322
    Diluted EPS Excluding Extraordinary Items -2.18049 -2.40943 -1.43197 -0.64858 -2.78987
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS -2.18049 -2.40943 -1.43197 -0.64858 -2.78987
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 10.654 7.802 14.688 5.573 4.284
    Revenue 10.654 7.802 14.688 5.573 4.284
    Total Operating Expense 67.155 65.603 60.514 65.212 56.034
    Selling/General/Admin. Expenses, Total 18.187 18.328 14.805 14.573 14.803
    Research & Development 48.968 47.275 45.709 50.639 41.231
    Operating Income -56.501 -57.801 -45.826 -59.639 -51.75
    Interest Income (Expense), Net Non-Operating 2.194 1.638 0.902 -0.172 -0.469
    Net Income Before Taxes -54.307 -56.163 -44.924 -59.811 -52.219
    Net Income After Taxes -54.307 -56.163 -44.924 -59.811 -52.219
    Net Income Before Extra. Items -54.307 -56.163 -44.924 -59.811 -52.219
    Net Income -54.307 -56.163 -44.924 -59.811 -52.219
    Income Available to Common Excl. Extra. Items -54.307 -56.163 -44.924 -59.811 -52.219
    Income Available to Common Incl. Extra. Items -54.307 -56.163 -44.924 -59.811 -52.219
    Diluted Net Income -54.307 -56.163 -44.924 -59.811 -52.219
    Diluted Weighted Average Shares 115.608 107.515 101.095 97.6419 95.7568
    Diluted EPS Excluding Extraordinary Items -0.46975 -0.52238 -0.44437 -0.61255 -0.54533
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.46975 -0.52238 -0.44437 -0.61255 -0.54533
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 319.219 188.898 258.58 101.326 74.305
    Cash and Short Term Investments 280.712 177.947 255.094 99.79 70.131
    Cash & Equivalents 128.885 177.947 255.094 62.351 59.634
    Total Receivables, Net 30 0 0.459
    Accounts Receivable - Trade, Net 30 0 0.459
    Prepaid Expenses 8.507 10.951 3.486 1.536 3.715
    Total Assets 334.34 206.111 273.399 107.541 78.502
    Property/Plant/Equipment, Total - Net 14.46 14.857 12.666 4.762 2.694
    Property/Plant/Equipment, Total - Gross 22.202 22.539 20.301 11.971 9.055
    Accumulated Depreciation, Total -7.742 -7.682 -7.635 -7.209 -6.361
    Other Long Term Assets, Total 0.661 2.356 2.153 1.453 1.503
    Total Current Liabilities 91.533 47.523 30.003 24.07 69.425
    Accounts Payable 13.951 12.321 8.34 7.296 10.727
    Accrued Expenses 45.982 31.019 17.583 11.205 12.375
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 31.36 3.944 3.987 4.815 46.323
    Total Liabilities 242.283 84.37 45.312 29.223 69.707
    Total Long Term Debt 25.132 25.075 5.151 4.476 0
    Other Liabilities, Total 125.618 11.772 10.158 0.677 0.282
    Total Equity 92.057 121.741 228.087 78.318 8.795
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    Common Stock 0.011 0.007 0.007 0.005 0.003
    Additional Paid-In Capital 746.889 572.213 508.499 270.662 172.966
    Retained Earnings (Accumulated Deficit) -654.691 -450.479 -280.419 -192.374 -164.166
    Total Liabilities & Shareholders’ Equity 334.34 206.111 273.399 107.541 78.502
    Total Common Shares Outstanding 105.145 73.7091 68.8413 45.388 23.2345
    Short Term Investments 151.827 0 37.439 10.497
    Long Term Investments
    Other Equity, Total -0.152 0 0.025 -0.008
    Current Port. of LT Debt/Capital Leases 0.24 0.239 0.093 0.754
    Long Term Debt 24.929 24.626 4.977 4.201
    Capital Lease Obligations 0.203 0.449 0.174 0.275
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 281.807 319.219 300.037 237.079 241.47
    Cash and Short Term Investments 273.919 280.712 290.126 225.128 230.057
    Cash & Equivalents 122.825 128.885 184.082 135.338 230.057
    Prepaid Expenses 7.888 8.507 9.911 11.951 11.413
    Total Assets 296.195 334.34 314.85 252.351 258.267
    Property/Plant/Equipment, Total - Net 13.8 14.46 14.197 14.548 14.55
    Other Long Term Assets, Total 0.588 0.661 0.616 0.724 2.247
    Total Current Liabilities 83.402 91.533 88.794 71.47 56.463
    Accounts Payable 18.156 13.951 13.732 8.158 9.775
    Accrued Expenses 35.492 45.982 43.901 36.848 29.879
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 29.754 31.6 31.161 26.464 16.809
    Total Liabilities 231.901 242.283 224.621 118.317 117.741
    Total Long Term Debt 25.004 24.929 24.853 24.777 24.702
    Long Term Debt 25.004 24.929 24.853 24.777 24.702
    Other Liabilities, Total 123.495 125.821 110.974 22.07 36.576
    Total Equity 64.294 92.057 90.229 134.034 140.526
    Common Stock 0.011 0.011 0.01 0.01 0.009
    Additional Paid-In Capital 775.125 746.889 700.217 684.106 638.254
    Retained Earnings (Accumulated Deficit) -710.854 -654.691 -609.767 -549.956 -497.737
    Other Equity, Total 0.012 -0.152 -0.231 -0.126
    Total Liabilities & Shareholders’ Equity 296.195 334.34 314.85 252.351 258.267
    Total Common Shares Outstanding 109.061 105.145 98.5826 97.1664 87.0731
    Property/Plant/Equipment, Total - Gross 22.202
    Current Port. of LT Debt/Capital Leases
    Preferred Stock - Non Redeemable, Net 0 0 0 0
    Accumulated Depreciation, Total -7.742
    Capital Lease Obligations
    Short Term Investments 151.094 151.827 106.044 89.79
    Total Receivables, Net 0 30
    Accounts Receivable - Trade, Net 0 30
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -204.212 -170.06 -88.045 -28.208 -64.257
    Cash From Operating Activities -49.363 -139.988 -74.696 -67.744 -55.216
    Cash From Operating Activities 0.927 0.855 1.01 1.245 1.257
    Non-Cash Items 20.823 19.132 7.234 4.753 3.718
    Changes in Working Capital 133.099 10.085 5.105 -45.534 4.066
    Cash From Investing Activities -152.716 -0.648 37.027 -27.293 87.195
    Capital Expenditures -2.197 -0.648 -0.473 -0.605 -1.37
    Other Investing Cash Flow Items, Total -150.519 0 37.5 -26.688 88.565
    Cash From Financing Activities 153.017 63.646 230.412 97.704 1.064
    Issuance (Retirement) of Stock, Net 153.289 2.477 167.689 92.826 1.064
    Net Change in Cash -49.062 -76.99 192.743 2.667 33.043
    Cash Interest Paid 2.463 0.429 0.234 0.132
    Issuance (Retirement) of Debt, Net -0.272 61.428 62.723 4.878
    Financing Cash Flow Items 0 -0.259
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -56.163 -204.212 -159.288 -99.477 -47.258
    Cash From Operating Activities -29.005 -49.363 1.866 -52.731 -7.955
    Cash From Operating Activities 0.319 0.927 0.645 0.432 0.205
    Non-Cash Items 5.148 20.823 16.386 11.11 5.679
    Cash Interest Paid 0.791 2.463 1.746 1.1 0.531
    Changes in Working Capital 21.691 133.099 144.123 35.204 33.419
    Cash From Investing Activities 1.396 -152.716 -107.29 -90.799 -0.329
    Capital Expenditures -0.911 -2.197 -1.412 -0.986 -0.329
    Other Investing Cash Flow Items, Total 2.307 -150.519 -105.878 -89.813
    Cash From Financing Activities 21.549 153.017 111.559 100.921 60.394
    Financing Cash Flow Items -0.15 0 0 0 0
    Issuance (Retirement) of Stock, Net 21.764 153.289 111.766 101.063 60.47
    Issuance (Retirement) of Debt, Net -0.065 -0.272 -0.207 -0.142 -0.076
    Net Change in Cash -6.06 -49.062 6.135 -42.609 52.11

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Mersana Therapeutics, Inc. Company profile

    About Mersana Therapeutics Inc

    Mersana Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing antibody drug conjugates (ADCs). The Company’s platforms include Dolaflexin and Dolasynthen. Its product candidates include upifitamab rilsodotin (UpRi, XMT-1536) and XMT-1592. The Company’s early stage programs include B7-H4-targeted Dolasynthen ADC, XMT-1660, as well as candidates leveraging the Immunosynthen platform. UpRi is an ADC utilizing the Company’s Dolaflexin platform and targeting NaPi2b, which is an antigen broadly expressed in ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma. XMT-1592 uses the Company’s Dolasynthen platform and targets NaPi2b.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Mersana Therapeutics Inc revenues decreased 95% to $43K. Net loss increased 93% to $170.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research & Development - Balancing value increase of 93% to $122M (expense), General & Administrative - Balancing val increase of 53% to $28.5M (expense).

    Industry: Bio Therapeutic Drugs

    840 Memorial Dr
    CAMBRIDGE
    MASSACHUSETTS 02139
    US

    Income Statement

    • Annual
    • Quarterly

    News

    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    Cable coils near lows ahead of Fed and BoE rate decisions

    It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

    14:16, 19 September 2023

    FTSE 100 Technical Outlook - 18 September 2023

    In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

    06:55, 19 September 2023
    View of the City of London’s illuminated financial district skyline at dusk

    Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

    The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

    13:46, 15 September 2023
    Euro symbol at European Central Bank

    ECB MEETING: Dovish hike causes EUR/USD to drop further.

    ECB hikes another 25bps in September but signals that this may be the last one.

    12:43, 14 September 2023

    People also watch

    US100

    14,767.30 Price
    -1.200% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0039%
    Overnight fee time 21:00 (UTC)
    Spread 1.8

    BTC/USD

    26,457.10 Price
    -2.500% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    ETH/USD

    1,579.01 Price
    -2.920% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 5.40

    XRP/USD

    0.51 Price
    -2.760% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading